Status and phase
Conditions
Treatments
About
This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC. The anticipated time on study treatment is 1-2 years, and the target sample size is greater than (>) 500 individuals.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Additional exclusion criteria concerning ribavirin:
Primary purpose
Allocation
Interventional model
Masking
737 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal